Phase 1 clinical trial long-term follow-up confirms cartilage regeneration and pain relief, raising expectations for Phase 2a trial success
[by Sung, Jae Jun] Kangstem Biotech announced on May 29 that its knee osteoarthritis treatment candidate, 'OSCA', demonstrates improved therapeutic effects lasting 12 months with a single injection in the Phase 1 clinical trial. Based on these results, the company stated that the possibility of success in the ongoing Phase 2a clinical trial has been further increased.
According to Kangstem 바카라사이트 카지노판, a 12-month long-term follow-up MRI analysis of participants in the Phase 1 clinical trial confirmed cartilage regeneration and restoration of damaged subchondral bone in a significant number of patients receiving medium and high doses. Notably, all patients in the high-dose group exhibited overall improvements in cartilage degradation, structural abnormalities, edema, synovitis, and meniscal damage. Furthermore, the company reported an improvement in patients’ quality of life, attributed to the relief of severe pain symptoms.
"We confirmed the potential for long-term therapeutic efficacy, as the treatment effects observed at six months were sustained or further improved over time," said Bae Yohan, Executive Managing Director of Clinical Development Division at Kangstem 바카라사이트 카지노판. "Consequently, patient enrollment for the Phase 2a clinical trial is progressing rapidly, and the prospects for collaboration with global markets and partners have also increased," he added.